

August 12, 2025

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: **526783**

Dear Sir / Madam,

Subject: Outcome of the Board meeting for approval of Unaudited Financial Results of the Company for the quarter ended June 30, 2025

In continuation of our letter dated July 30, 2025 regarding the captioned subject and pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Tuesday, August 12, 2025, has *inter alia*, considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2025. Copy of the same along with the Limited Review Report issued by the Statutory Auditors of the Company is enclosed.

Further, the Financial Results shall be published in the newspapers in compliance with Regulation 47 of the SEBI Listing Regulations and the same will also be available on the website of the Company at www.dragarwals.co.in

The meeting of the Board of Directors commenced at 12:15 p.m. and concluded at 12:50 p.m.

Kindly take the above information on record.

Thanking you,

Yours sincerely

For **Dr. Agarwal's Eye Hospital Limited**

Meenakshi Jayaraman

Company Secretary and Compliance Officer

Encl.: as above

Dr. Agarwal's Eye Hospital Limited

Regd. & Corporate Office

3rd Floor, Buhari Towers, No.4 Moores Road, Off Greams Road, Near Asan Memorial School, Chennai - 600 006.

Tel: +91 44 4378 7777 | +91 44 4378 7778 | CIN: L85110TN1994PLC027366 | GST No: 33AAACD2373G1Z2

Email: info@dragarwal.com | Website: www.dragarwal.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company"), for the quarter ended 30 June 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)

PRASANNA
VENKATESH
RAJAGOPALAN

Digitally signed by
PRASANNA VENKATESH
RAJAGOPALAN
Date: 2025.08.12
12:50:38 +05'30'

R. Prasanna Venkatesh
(Partner)
(Membership No. 214045)

Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greaves Road, Chennai - 600 006
Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

Dr Agarwals
Eye Hospital

(Amount in INR Crores except EPS)

Statement of Unaudited Financial Results for the Quarter Ended 30th June 2025

S.No.	Particulars	Quarter Ended			Year Ended
		30-Jun-25 (Unaudited)	31-Mar-25 (Refer Note 3)	30-Jun-24 (Unaudited)	31-Mar-25 Audited
1	Income				
	(a) Revenue from Operations	116.92	99.83	100.02	397.15
	(b) Other Income	0.80	0.10	0.40	5.09
	Total Income	117.72	99.93	100.42	402.24
2	Expenses				
	(a) Purchase of Stock-in-Trade	11.87	9.03	11.56	43.11
	(b) Changes in Inventories of Stock-in-Trade - (Increase) / Decrease	0.38	1.61	(1.41)	(1.16)
	(c) Surgical Lens including other consumables	13.89	10.97	11.89	47.67
	(d) Consultancy Charges for Doctors (Net)	15.39	13.84	14.24	53.27
	(e) Employee Benefit Expenses	22.18	19.95	17.57	78.32
	(f) Finance Costs	4.16	2.89	3.03	13.44
	(g) Depreciation and Amortisation Expense	10.58	10.20	9.87	39.45
	(h) Other Expenses	16.08	12.84	14.76	57.44
	Total Expenses	94.53	81.33	81.51	331.54
3	Profit before tax (1-2)	23.19	18.60	18.91	70.70
	Tax Expense				
	- Current Tax (including tax pertaining to earlier years)	5.92	2.02	5.21	15.81
	- Deferred Tax (Net)	0.01	0.59	(0.41)	0.24
4	Total tax expenses	5.93	2.61	4.80	16.05
5	Net Profit after tax for the period (3-4)	17.26	15.99	14.11	54.65
6	Other Comprehensive Income				
	(a) Items that will not be reclassified to the Statement of Profit and Loss				
	- Actuarial (loss) / gain on defined benefit obligation	0.06	0.59	0.03	0.22
	- Tax on items that will not be reclassified to the Statement of Profit and Loss	(0.02)	(0.15)	(0.01)	(0.06)
	Total Other Comprehensive income (net of tax)	0.04	0.44	0.02	0.16
7	Total Comprehensive Income (5+6)	17.30	16.43	14.13	54.81
8	Paid-up equity share capital (Face value INR 10/- each)	4.70	4.70	4.70	4.70
9	Reserves (Other Equity)				204.91
10	Earnings Per Equity Share (EPS) (Face value of INR 10/- each)				
	(a) Basic	36.72	34.02	30.02	116.28
	(b) Diluted	36.72	34.02	30.02	116.28
		(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)
	Additional Information:				
	Earnings before finance cost, depreciation, amortisation and tax (EBITDA) (Refer Foot Note (i))	37.93	31.69	31.81	123.59

See accompanying notes to the financial results

Foot note:

(i) The company has presented information on EBITDA additionally as a part of the statement of financial results as defined above.



Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006

Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

Dr Agarwals
Eye Hospital

Statement of Unaudited Financial Results for the quarter ended 30 June, 2025

Notes:

- 1 The unaudited financial results, which are published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 2 The above unaudited financial results have been reviewed by the Audit Committee and the same has been approved and taken on record by the Board of Directors at their meeting held on 12th August 2025. The above results for the quarter ended 30th June 2025 has also been subjected to limited review by the Statutory Auditors of the Company.
- 3 The comparative financial results for the quarter ended 31st March 2025 are balancing figures between the audited figures in respect of the financial year ended 31st March 2025 and the published unaudited year to date figures for the nine months ended 31st December 2024 which were subjected to limited review by the statutory auditors of the Company.
- 4 The Company operates in a single segment i.e. "Eye Care related sales and services" and does not have any additional disclosures to be made under Ind AS 108 - Operating Segments.
- 5 Figures for the previous periods, wherever necessary, have been regrouped/ reclassified to conform to the current period's presentation.



By order of the Board

[Signature]
Dr. Amar Agarwal

Chairman & Managing Director

DIN No. 00435684

Place : Chennai

Date : 12th August 2025



Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greaves Road, Chennai - 600 006

Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

(Amount in INR Crores except EPS)

Statement of Unaudited Financial Results for the Quarter ended 30th June 2025

Particulars	Quarter Ended		Year ended	
	30-Jun-25 (Unaudited)	31-Mar-25 (Refer Note 2)	30-Jun-24 (Unaudited)	31-Mar-25 Audited
Revenue from Operations	116.92	99.83	100.02	397.15
Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	23.19	18.60	18.91	70.70
Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	23.19	18.60	18.91	70.70
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	17.26	15.99	14.11	54.65
Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	17.30	16.43	14.13	54.81
Paid-up Equity Share Capital (Face Value of INR 10/- each)	4.70	4.70	4.70	4.70
Reserves (Other Equity)				204.91
Earnings Per Share (for continuing and discontinued operations) (Face Value of INR 10/- each):				
(a) Basic	36.72	34.02	30.02	116.28
(b) Diluted	36.72	34.02	30.02	116.28
	(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)

Notes:

- 1) The above is an extract of the detailed format of Quarterly Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Unaudited Financial Results is available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.dragarwal.com).
- 2) The Comparative financial results for the quarter ended 31st March 2025 are balancing figures between the audited figures in respect of the financial year ended 31st March 2025 and the published unaudited year to date figures for the nine months ended 31st December 2024 which were subjected to limited review by the Statutory Auditors of the Company.
- 3) Figures for the previous periods, wherever necessary, have been regrouped/reclassified to conform to the current period's presentation.

By order of the Board

Place : Chennai
Date : 12th August 2025



Agarwal

Dr. Amar Agarwal
Chairman & Managing Director
DIN No. 00435684